Stats: Women in Clinical Trials
Percentage of female participants in heart-related studies (reported in 2014), even though heart disease is the leading cause of death for women in the U.S.
The number of representatives in Congress currently co-sponsoring the Research for All Act. If it becomes law, it will increase the study and analysis of sex differences in biomedical research.
Year the Food and Drug Administration (FDA), concerned about the possible effects of experimental drugs on fetuses, banned all women of childbearing age from participating in clinical trials — including lesbians, women using birth control, and abstinent women. The ban lasted until 1993.
Percentage of randomized clinical trials studying depression in 2007 that did not analyze outcomes by gender, even though U.S. women are twice as likely as men to have the condition.
Percentage of the National Institutes of Health (NIH) budget used to fund research on women’s health issues.
Percentage of FDA-approved prescription drugs removed from the market between 1997 and 2001 because of their health risks to women.
Million dollars the NIH spent on women’s heart disease research in 2014. In comparison, $959 million was spent on women’s cancer research out of a total NIH budget of $30 billion.
Percentage increase in enrollments in the Gilda Radner Hereditary Cancer Program in 2014, spurred by Research for Her™, Cedars-Sinai’s groundbreaking online registry that matches women with research studies and clinical trials. The program consists of several research studies for women at elevated risk for breast and ovarian cancer, and is part of the Women’s Cancer Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.